Everolimus – a new approach in the treatment of renal cell carcinoma

References

• GuptaKMillerJDLiJZRussellMWCharbonneauCEpidemiological and socioeconomic burden of metastatic renal cell carcinoma; a literature reviewCancer Treat Rev20083419320518313224
   PubMed Web of Science ®Google Scholar
• JochamDRichterAHoffmannLAdjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomized controlled trialLancet200436359459914987883
   PubMed Web of Science ®Google Scholar
• MoyadMAReview of potential risk factors for kidney (renal cell) cancerSemin Urol Oncol200119428029311769880
   PubMedGoogle Scholar
• HornerMJRiesLAGKrapchoMSEER Cancer Statistics Review, 1975–2006National Cancer InstituteBethesda, MD http://seer.cancer.gov/csr/1975_2006/, based on November 2008 SEER data submission, posted to the SEER web site,2009
   Google Scholar
• MaldazysJDdeKernionJBPrognostic factors in metastatic renal carcinomaJ Urol19861363763793735498
   PubMed Web of Science ®Google Scholar
• RiniBICampbellSCEscudierBRenal Cell CarcinomaLancet20093731119113219269025
   PubMed Web of Science ®Google Scholar
• BanksRETirukondaPTaylorCGenetic and epigenetic analysis of von Hippel-Lindau (VHL) gene alterations and relationship with clinical variables in sporadic renal cancerCancer Res2006662000201116488999
   PubMed Web of Science ®Google Scholar
• SemenzaGLHIF-1 and human disease: one highly involved factorGenes Dev2000141983199110950862
   PubMed Web of Science ®Google Scholar
• HickeyMMSimonMCRegulation of angiogenesis by hypoxia and hypoxia-inducible factorsCurr Top Dev Biol20067621725717118268
   PubMed Web of Science ®Google Scholar
• GnarraJRToryKWengYMutations of the VHL tumor suppressor gene in renal carcinomaNat Gen199478590
   PubMed Web of Science ®Google Scholar
• SatoKTsuchiyaNSasakiRIncreased serum levels of vascular endothelial growth factor in patients with renal cell carcinomaJpn J Cancer Research19999087487910543260
   PubMedGoogle Scholar
• HudsonCCLiuMChiangGGOtternessDMRegulation of hypoxia-inducible factor-1alpha expression and function by the mammalian target of rapamycinMol Cell Biol2002227004701412242281
   PubMed Web of Science ®Google Scholar
• RobbVAKarbowniczekMKlien-SzantoAJActivation of the mTOR signaling pathway in renal clear cell carcinomaJ Urol200717734633517162089
   PubMed Web of Science ®Google Scholar
• CorradettiMNGuanKLUpstream of the mammalian target of rapamycin: Do all roads pass through mTOR?Oncogene2006256347636017041621
   PubMed Web of Science ®Google Scholar
• MamaneYPetroulakisELeBacquerOmTOR, translation initiation and cancerOncogene2006256416642217041626
   PubMed Web of Science ®Google Scholar
• FaivreSKroemerGRaymondECurrent development of mTOR inhibitors as anticancer agentsNat Rev Drug Discovery20065671688
   PubMed Web of Science ®Google Scholar
• HayNSonenbergNUpstream and downstream of mTORGenes Dev2004181926194515314020
   PubMed Web of Science ®Google Scholar
• KwiatkowskiDJRhebbing up mTOR: new insights on TSC1 and TSC 2, and the pathogenesis of tuberous sclerosisCancer Biol Ther2003247147614614311
   PubMed Web of Science ®Google Scholar
• InokiKLiYXuTGuanKLRheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signallingGenes Dev2003171829183412869586
   PubMed Web of Science ®Google Scholar
• GuertinDASabatiniDMDefining the role of mTOR in cancerCancer Cell20071292217613433
   PubMed Web of Science ®Google Scholar
• SabatiniDMmTOR and cancer: insights into a complex relationshipNat Rev Cancer2006672973416915295
   PubMed Web of Science ®Google Scholar
• ToschiALeeEGadirNDifferential dependence of Hypoxiainducible factors 1α and 2α on mTORC1 and mTORC2J Biol Chem2008283344953449918945681
   PubMed Web of Science ®Google Scholar
• LaneHAWoodJMMcSheehyPMmTOR inhibitor RAD001 (Everolimus) has antiangiogenic/vascular properties distinct from a VEGF tyrosine kinase inhibitorClin Cancer Res2009151612162219223496
   PubMed Web of Science ®Google Scholar
• PhungTLEyiah-MensahGO’DonnellRKEndothelial Akt signalling is rate-limiting for rapamycin inhibition of mouse mammary tumor progressionCancer Res2007675070507517545582
   PubMed Web of Science ®Google Scholar
• ZacharyIVEGF signalling: integration and multi-tasking in endothelial cell biologyBiochem Soc Trans2003311171117714641020
   PubMed Web of Science ®Google Scholar
• HudesGCarducciMTomczakPTemsirolimus, interferon alfa, or both for advanced renal-cell carcinomaN Engl J Med20073562271228117538086
   PubMed Web of Science ®Google Scholar
• IsaacsJSJungYJMoleDRHIF over expression correlates with biallelic loss of fumarate hydratase in renal cell cancer: novel role of fumarate in regulation of HIF stabilityCancer Cell2005814315316098467
   PubMed Web of Science ®Google Scholar
• MotzerRJMazumdarMBacikJBergWAmsterdamAFerraraJSurvival and prognostic stratification of 670 patients with advanced renal cell carcinomaJ Clin Oncol1999172530254010561319
   PubMed Web of Science ®Google Scholar
• MekhailTMAbou-JawdeRMBoumerhiGValidation and extension of the Memorial Sloan Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinomaJ Clin Oncol20052383284115681528
   PubMed Web of Science ®Google Scholar
• HashemolhosseiniSNagamineYMorleySJRapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stabilityJ Biol Chem199827314424144299603954
   PubMed Web of Science ®Google Scholar
• JefferiesHBReinhardCKozmaSCThomasGRapamycin selectively represses translation of the “polypyrimidine tract” mRNA familyProc Natl Acad Sci U S A199491444144458183928
   PubMed Web of Science ®Google Scholar
• PearsonRBDennisPBHanJWThe principal target of rapamycin-induced p70s6k inactivation is a novel phosphorylation site within a conserved hydrophobic domainEMBO J199514527952877489717
   PubMed Web of Science ®Google Scholar
• DufnerAThomasGRibosomal S6 kinase signaling and the control of translationExp Cell Res199925310010910579915
   PubMed Web of Science ®Google Scholar
• BoulayAZumstein-MeckerSStephanCAntitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cellsCancer Res20046425226114729632
   PubMed Web of Science ®Google Scholar
• O’DonnellAFaivreSBurrisHA3rdPhase I Pharmacokinetic and Pharmacodynamic study of the oral mammalian target of Rapamycin inhibitor Everolimus in patients with advanced solid tumoursJ Clin Oncol2008261588159518332470
   PubMed Web of Science ®Google Scholar
• Everolimus-Summary of Product CharacteristicsNovartis Pharma AGBasel, Switzerland
   Google Scholar
• TaberneroJRojoFCalvoEDose- and Schedule-dependent inhibition of mammalian target of Rapamycin pathway with Everolimus: A phase I tumour pharmacodynamic study in patients with advanced solid tumoursJ Clin Oncol2008261603161018332469
   PubMed Web of Science ®Google Scholar
• AmatoRJJacJGiessingerSSaxenaSWillisJPA Phase II study with a daily regimen of the oral mTOR inhibitor RAD001(Everolimus) in patients with metastatic clear cell renal cell cancerCancer20091152438244619306412
   PubMed Web of Science ®Google Scholar
• WhorfRCHainsworthJDSpigelDRPhase II study of bevacizumab and everolimus (RAD001) in the treatment of advanced renal cell carcinoma (RCC)J Clin Oncol20082615S5010
   Web of Science ®Google Scholar
• MotzerRJEscudierBOudardSEfficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trialLancet200837244945618653228
   PubMed Web of Science ®Google Scholar
• A practical guide to managing adverse events with Afinitor2009Novartis Pharma AGBasel, Switzerland
   Google Scholar
• www.clinicaltrials.gov. Accessed October 31, 2009.
   Google Scholar
• EscudierBGoupilMGMassardCSequential Therapy in Renal Cell CarcinomaCancer200911510 suppl22212226
   Web of Science ®Google Scholar
• AtkinsMBChoueiriTKChoDReganMSignorettiSTreatment selection for patients with metastatic renal cell carcinomaCancer200911510 Suppl2327233319402069
   PubMed Web of Science ®Google Scholar
• WanXHarkavyBShenNRapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanismOncogene2007261932194017001314
   PubMed Web of Science ®Google Scholar
• O’ReillyKERojoFSheQmTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AktCancer Res2006615001508
   Web of Science ®Google Scholar
• ShiYYanHFrostPMammalian target of rapamycininhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascadeMol Cancer Ther200541533154016227402
   PubMed Web of Science ®Google Scholar